Insider Transactions in Q1 2022 at Heron Therapeutics, Inc. (HRTX)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 13
2022
|
Kimberly Manhard EVP, Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-22.15%
|
$16,096
$8.3 P/Share
|
|
Jan 13
2022
|
Kimberly Manhard EVP, Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+27.56%
|
-
|
|
Jan 13
2022
|
Lisa Peraza VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
966
-5.79%
|
$7,728
$8.3 P/Share
|
|
Jan 13
2022
|
Lisa Peraza VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,485
+7.0%
|
-
|
|
Jan 13
2022
|
John Poyhonen President & CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-6.79%
|
$16,096
$8.3 P/Share
|
|
Jan 13
2022
|
John Poyhonen President & CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+9.04%
|
-
|
|
Jan 13
2022
|
Barry D Quart Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,219
-4.28%
|
$41,752
$8.3 P/Share
|
|
Jan 13
2022
|
Barry D Quart Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,768
+7.51%
|
-
|
|
Jan 13
2022
|
David Leslie Szekeres EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-20.54%
|
$16,096
$8.3 P/Share
|
|
Jan 13
2022
|
David Leslie Szekeres EVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+25.54%
|
-
|